Treatment for peripheral arterial obstructive disease: An appraisal of the economic outcome of complications

被引:19
|
作者
Flu, Hans [2 ]
van der Hage, Jos H. [2 ]
Knippenberg, Bob [2 ]
Merkus, Jos W. [2 ]
Hamming, Jaap F.
Lardenoye, Jan Willem H. [1 ]
机构
[1] Leiden Univ Med Ctr, Dept Vasc Surg, NL-2300 RC Leiden, Netherlands
[2] Haga Hosp Locat Leyweg, Dept Vasc Surg, The Hague, Netherlands
关键词
D O I
10.1016/j.jvs.2008.03.029
中图分类号
R61 [外科手术学];
学科分类号
摘要
Objective: This study determined the average estimated total costs after treatment for peripheral arterial occlusive disease (PAOD) and evaluated the effect of postoperative complications and their consequences for the total Costs. Methods. Cost data on all admissions involving treatment for PAOD from January 2007 until July 2007 were collected. A prospective analysis was made using the patient-related risk factor and comorbidity (Society for Vascular Surgery/International Society of Cardiovascular Surgeons) classification, primary and secondary treatment, and prospectively registered complications. At admission, patients without complications were placed in group A, and those with complications were in group B. Prospectively registered complications were divided into patient management (I), surgical technique (II), patient's disease (III), and outside surgical department (IV). The consequences of these were divided into minor complication, no long-term consequence (1A), additional medication or transfusion (1B), surgical reoperation (2A), prolonged hospital stay (2B), irreversible physical damage (3), and death (4). The main outcome measures were total costs of patients and costs per patient (PP), with or without the presence of complications, cost of complications and costs per complication (PC), and the costs of their consequences calculated in euros (epsilon). Results. Ninety patients (mean age, 71.4 years; 59% men) were included. Group B patients had a significantly higher American Society of Anesthesiologists (4) and Fontaine (3) classification and more secondary procedures. Total costs were epsilon 1,716,852: group A, epsilon 512,811 (PP epsilon 12,820); and group B, epsilon 1,204,042 (PP epsilon 24,081). The costs of the 115 complications were epsilon 568,500 (PC is an element of 4943). Split by the cause of the complication, costs were I, epsilon 95,924 (PC epsilon 2998); II, epsilon 163,137 (PC epsilon 8157); III, epsilon 289,578 (PC epsilon 5171); and IV, epsilon 19,861 (PC epsilon 2837). The increase of costs in group B was mainly caused by additional medication or transfusion (1B) epsilon 348,293 (61.3%), a surgical reoperation (2A) epsilon 118,054 (20.8%), or prolonged hospital stay (2B) epsilon 60,451 (10.6%). Patients who died caused 23% of the total costs. Conclusion: Complications cause an increase of the average estimated total costs in the treatment for peripheral arterial occlusive disease and are responsible for 33% of these total costs. The most expensive complications were errors in surgical technique and patient's disease, resulting in surgical reoperation or additional medication, or both, or transfusion, the two most expensive consequences.
引用
收藏
页码:368 / 376
页数:9
相关论文
共 50 条
  • [31] Medical treatment of peripheral arterial disease
    Curci, JA
    Sanchez, LA
    CURRENT OPINION IN CARDIOLOGY, 2003, 18 (06) : 425 - 430
  • [32] ADVANCES IN TREATMENT OF PERIPHERAL ARTERIAL DISEASE
    MALT, RA
    MORAN, JM
    PRACTITIONER, 1966, 197 (1180) : 484 - &
  • [33] Diagnosis and Treatment of Peripheral Arterial Disease
    Hennion, Duane R.
    Siano, Kelly A.
    AMERICAN FAMILY PHYSICIAN, 2013, 88 (05) : 306 - 310
  • [34] Diagnosis and treatment of peripheral arterial disease
    Fried, RE
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (03): : 315 - 315
  • [35] The Arterial Anastomosis in Liver Transplantation: Complications, Treatment and Outcome
    Pakosz-Golanowska, Monika
    Lubikowski, Jerzy
    Post, Mariola
    Jarosz, Konrad
    Zasada-Cedro, Katarzyna
    Milkiewicz, Piotr
    Wojcicki, Maciej
    HEPATO-GASTROENTEROLOGY, 2010, 57 (104) : 1477 - 1482
  • [36] Rivaroxaban in patients with ischaemic chronic cardiomyopathy and obstructive peripheral arterial disease: rationale for treatment and results
    Savonitto, Stefano
    Pelizzoli, Silvia
    Selva, Antonia Maria
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2020, 22 (0E) : E137 - E141
  • [37] Outcome of Treatment of Peripheral Arterial Disease (PAD) by Insurer Status in New York State
    Drujski, M. L.
    O'Brien-Irr, M. S.
    Dosluoglu, H. H.
    Harris, L. M.
    JOURNAL OF VASCULAR SURGERY, 2009, 50 (04) : 971 - 972
  • [38] ARTERIOSCLEROTIC RENOVASCULAR STENOSES IN PATIENTS WITH PERIPHERAL ARTERIAL OBSTRUCTIVE DISEASE
    KUHLMANN, U
    STEURER, J
    VETTER, W
    SCHNEIDER, E
    SIEGENTHALER, W
    KIDNEY INTERNATIONAL, 1981, 20 (01) : 155 - 155
  • [39] Gait of Patients with Peripheral Obstructive Arterial Disease and Intermittent Claudication
    Grams, Samantha Torres
    Damiano, Ana Paula
    Monte, Fernanda Guidarini
    Mandelli, Marcelo Barbosa
    de Carvalho, Tales
    REVISTA BRASILEIRA DE MEDICINA DO ESPORTE, 2009, 15 (04) : 255 - 259
  • [40] Outcome of Peripheral Arterial Disease in Patients with ESKD on Hemodialysis
    Oweis, Ashraf Omar
    Alshelleh, Sameeha A.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2024, 35 (10):